Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Hep C Discussion Forum -> Hep C News -> Ongoing real world study reports high SVR rates for VIEKIRAX + EXVIERA in Gen 1
Post Info TOPIC: Ongoing real world study reports high SVR rates for VIEKIRAX + EXVIERA in Gen 1
Cinnamon Girl


Guru

Status: Offline
Posts: 5629
Date:
Ongoing real world study reports high SVR rates for VIEKIRAX + EXVIERA in Gen 1
Permalink  
 

New real world interim data from the independent AMBER study were presented for AbbVie's VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) with or without ribavirin in gen 1 chronic hep C infected patients.  The primary endpoint of the study is the percentage of patients achieving sustained virologic response at 12 weeks post-treatment (SVR12).  This study of Polish patients who reached post-treatent at week 12 (n=40 of 186 enrolled to date), demonstrated 98 percent (n=39/40) SVR12.  These results further help to support the GT1 data shown in AbbVie's Phase 3 clinical trial development program.  Interim data from the AMBER study were presented at the Viral Hepatitis Congress in Frankfurt, Germany.

Link to full details of press release...

http://www.prnewswire.co.uk/news-releases/ongoing-real-world-study-reports-high-sustained-viral-response-rates-with-viekirax-ombitasvirparitaprevirritonavir-tablets--exviera-dasabuvir-tablets-in-genotype-1-hepatitis-c-patients-526585651.html



__________________

Jill 

(71 yo, lives in UK)

Was Gen 3a, 

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT, 

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

 

 
Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.
Hep C Discussion Forum -> Hep C News -> Ongoing real world study reports high SVR rates for VIEKIRAX + EXVIERA in Gen 1
Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.